Abstract | BACKGROUND: METHODS: In a nested case-control study we compared maternal serum levels of PAPP-A, SP1, HPL and placenta growth factor (PLGF) at 17, 25 and 33 weeks in pregnancies developing preeclampsia without fetal growth restriction (n = 28), or characterized by a growth-retarded fetus (n = 25), with gestation-matched controls (n = 65). The proteins were quantified using microplate enzyme immunometric assays and the serum levels at 17, 25 and 33 weeks compared between the three groups by nonparametric statistical tests. RESULTS: In pregnancies with subsequent preeclampsia PAPP-A, SP1, HPL and PLGF were reduced at 17 weeks of gestation whereas at 25 and 33 weeks only PLGF remained below the controls. In growth-restricted pregnancies PAPP-A, SP1 and HPL were reduced at 17 weeks, and only HPL continued to be strongly affected thereafter. CONCLUSION:
|
Authors | Nick A Bersinger, Rønnaug A Ødegård |
Journal | Acta obstetricia et gynecologica Scandinavica
(Acta Obstet Gynecol Scand)
Vol. 83
Issue 1
Pg. 37-45
(Jan 2004)
ISSN: 0001-6349 [Print] United States |
PMID | 14678084
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Biomarkers
- PGF protein, human
- Pregnancy Proteins
- Pregnancy-Specific beta 1-Glycoproteins
- Placenta Growth Factor
- Placental Lactogen
- Pregnancy-Associated Plasma Protein-A
|
Topics |
- Adult
- Biomarkers
(blood)
- Case-Control Studies
- Female
- Fetal Growth Retardation
(blood)
- Humans
- Placenta Growth Factor
- Placental Lactogen
(blood)
- Pre-Eclampsia
(blood)
- Pregnancy
- Pregnancy Proteins
(blood)
- Pregnancy Trimester, Second
(blood)
- Pregnancy Trimester, Third
(blood)
- Pregnancy-Associated Plasma Protein-A
(metabolism)
- Pregnancy-Specific beta 1-Glycoproteins
(metabolism)
- Prospective Studies
|